dc.contributor.author | Bliss, J | |
dc.contributor.author | Porta, N | |
dc.contributor.author | Emson, M | |
dc.contributor.author | Miller, S | |
dc.contributor.author | Morden, J | |
dc.date.accessioned | 2022-01-18T15:16:01Z | |
dc.date.available | 2022-01-18T15:16:01Z | |
dc.date.issued | 2022-04-01 | |
dc.identifier.citation | Clinical Cancer Research | |
dc.identifier.issn | 1078-0432 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4965 | |
dc.language.iso | eng | |
dc.publisher | American Association for Cancer Research | |
dc.rights.uri | http://www.rioxx.net/licenses/all-rights-reserved | |
dc.title | Combined Peri-operative Lapatinib and Trastuzumab in Early HER2 Positive Breast Cancer can Identify Early Responders: Results from the UK EPHOS-B Trial (CRUK/08/002 | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2021-12-20 | |
rioxxterms.version | AM | |
rioxxterms.licenseref.startdate | 2021-12-20 | |
dc.relation.isPartOf | Clinical Cancer Research | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Clinical Trials & Statistics Unit | |
pubs.publication-status | Accepted | |
pubs.embargo.terms | Not known | |
icr.researchteam | Clinical Trials & Statistics Unit | |
dc.contributor.icrauthor | Bliss, Judith | |
dc.contributor.icrauthor | Porta, Nuria | |
dc.contributor.icrauthor | Emson, Marie | |